GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Innovus Pharmaceuticals Inc (OTCPK:INNV) » Definitions » YoY EPS Growth

Innovus Pharmaceuticals (Innovus Pharmaceuticals) YoY EPS Growth : 32.50% (As of Sep. 2019)


View and export this data going back to 2008. Start your Free Trial

What is Innovus Pharmaceuticals YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Innovus Pharmaceuticals's YoY EPS Growth for the quarter that ended in Sep. 2019 was 32.50%.

Innovus Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Sep. 2019 was $-0.81.

Innovus Pharmaceuticals YoY EPS Growth Historical Data

The historical data trend for Innovus Pharmaceuticals's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovus Pharmaceuticals YoY EPS Growth Chart

Innovus Pharmaceuticals Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.04 60.00 -87.50 72.57 3.70

Innovus Pharmaceuticals Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.29 5.71 21.36 29.79 32.50

Innovus Pharmaceuticals YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Innovus Pharmaceuticals's YoY EPS Growth for the fiscal year that ended in Dec. 2018 is calculated as:

YoY EPS Growth (A: Dec. 2018 )
=(Earnings per Share (Diluted) (A: Dec. 2018 )-Earnings per Share (Diluted) (A: Dec. 2017 ))/ | Earnings per Share (Diluted) (A: Dec. 2017 ) |
=(-4.16--4.32)/ | -4.32 |
=3.70 %

Innovus Pharmaceuticals's YoY EPS Growth for the quarter that ended in Sep. 2019 is calculated as:

YoY EPS Growth (Q: Sep. 2019 )
=(Earnings per Share (Diluted) (Q: Sep. 2019 )-Earnings per Share (Diluted) (Q: Sep. 2018 )) / | Earnings per Share (Diluted) (Q: Sep. 2018 )) |
=(-0.81--1.2)/ | -1.2 |
=32.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovus Pharmaceuticals YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Innovus Pharmaceuticals's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovus Pharmaceuticals (Innovus Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Innovus Pharmaceuticals Inc (OTCPK:INNV) » Definitions » YoY EPS Growth
Comparable Companies
BOM:524711 CXUS BOM:524202 CYIG XCNQ:VENI ASX:AZT BOM:530233 WAR:CBD FRA:ELN XSAT:ACUC NSE:PAR BOM:540694 ETST OSTO:GABA BOM:531726 XCNQ:GSTR BUD:NUTEX MCOA SGX:BFK BUE:ROSE
Traded in Other Exchanges
N/A
Address
8845 Rehco Road, San Diego, CA, USA, 92121
Website
http://www.innovuspharma.com
Innovus Pharmaceuticals Inc is engaged in the healthcare industry. It is a specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. Innovus distributes OTC medicines and consumer and health products directly, through commercial partners to primary care physicians, urologists, gynecologists and therapists, and directly to consumers through its on-line channels, retailers, and wholesalers.
Executives
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Vivian H Liu director
Henry Jemil Esber director 38 ANGELL BROOK DRIVE, WEST BOYLSTON MA 01853
Randy Berholtz officer: EVP, CORPORATE DEVELOPMENT 6330 NANCY RIDGE DRIVE, SUITE 103, SAN DIEGO CA 92121
Ryan J Selhorn officer: VP, CFO 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Bassam Damaj director, officer: CHIEF EXECUTIVE OFFICER C/O BIO-QUANT, INC., 6330 NANCY RIDGE DRIVE, SUITE 103, SAN DIEGO CA 92121
Robert Hoffman officer: Chief Financial Officer ARENA PHARMACEUTICALS INC, 6166 NANCY RIDER DRIVE, SAN DIEGO CA 92121
Morgan R Brown officer: See remarks 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Jacki Bartholomew director 175 SOUTH MAIN STREET, NO 1212, SALT LAKE CITY UT 84111
Thomas L Harkness director, officer: Secretary 175 SOUTH MAIN STREET, NO 1212, SALT LAKE CITY UT 84111
Wallace Boyack director, 10 percent owner, officer: President & CEO 175 S MAIN ST, NO 1212, SALT LAKE CITY UT 84111